News

CEPI awards up to US$21 million to Themis for Phase 3 Chikungunya Vaccine Development

Details

Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a second partnering agreement under which CEPI, with support from the EU’s Horizon 2020 programme, will provide up to US$21 million of non-dilutive capital for Themis’ Phase 3-ready Chikungunya vaccine (MV-CHIK). The funding will underwrite a collaborative effort to accelerate regulatory approval of Themis’ Chikungunya vaccine and ensure that at-risk populations have access to the vaccine. 

US patent grants strengthen SNIPR BIOME’s approach to enhance immuno-oncology outcomes by microbiome modulation

Details

SNIPR BIOME today announced that the US Patent & Trademark Office has granted 2 patents covering concepts of shaping patients’ microbiomes to positively influence immuno-oncology therapies. The patents, US10,300,138 and US10,300,139 entitled “Selectively Altering Microbiota for Immune Modulation”, protect the modulation of anti-PD-1 and anti-PD-L1 immunotherapies using CRISPR, TALENs or any other guided nuclease to shape microbiota of patients. 

Wellington Partners co-leads €30 million Series A financing in Confo Therapeutics

Details

Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The investment was co-led by BioGeneration Ventures (BGV) and Wellington Partners, with the addition of new investors Fund+ and Perceptive Advisors. Existing investors Capricorn Health-Tech Fund, Qbic, Participatie Maatschappij Vlaanderen NV (PMV), MINTS (University of Michigan), V-Bio Ventures and VIB also took part in the current financing round.


  1. SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials
  2. Themis receives FDA fast track designation for Chikungunya vaccine candidate
  3. Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
  4. AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
© Wellington Partners, 2019.